United States · FDA National Drug Code directory
BEOVU
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0078-0827_8b8e71f4-7d7e-40b5-a942-89ac3b6c0c6c
- Product NDC
- 0078-0827
- Form
- INJECTION, SOLUTION
- Composition / generic term
- brolucizumab
- Labeler
- Novartis Pharmaceuticals Corporation
- Marketing category
- BLA
- Marketing start / end (source format)
- 20191007
- Source listing expiry
- 20261231
Source-listed ingredients
- BROLUCIZUMAB — 6 mg/.05mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 SYRINGE, GLASS in 1 CARTON (0078-0827-60) / .05 mL in 1 SYRINGE, GLASS · 0078-0827-60
- 1 SYRINGE, GLASS in 1 CARTON (0078-0827-98) / .05 mL in 1 SYRINGE, GLASS · 0078-0827-98
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →